GE HealthCare in Talks to Acquire Sofie Biosciences for About $1 Bn

The potential acquisition would be GE HealthCare’s second major purchase since it became an independent publicly traded company following its separation from General Electric in 2023.

GE HealthCare Technologies is in talks to acquire Sofie Biosciences, a private equity-backed developer of radioactive chemicals used in cancer imaging, in a deal valued at approximately $1 billion, according to people familiar with the matter.

An agreement could be announced as early as next week if negotiations proceed without last-minute complications. The potential acquisition would be GE HealthCare’s second major purchase since it became an independent publicly traded company following its separation from General Electric in 2023.

Sofie Biosciences develops radiopharmaceuticals and radioisotopes used in positron emission tomography (PET) scans. The company is developing radioisotopes targeting certain gastroesophageal and pancreatic cancers, areas where PET imaging can support cancer detection and evaluation.

The acquisition would strengthen GE HealthCare’s pharmaceutical diagnostics division, which provides imaging agents and other products used alongside diagnostic scans. GE HealthCare is a major manufacturer of medical imaging systems, including MRI, CT and PET scanners.

Sofie remains largely owned by its founders and management, alongside private equity firm Trilantic. The investment firm acquired a 25.8% stake in Sofie in 2024 at a valuation of up to $550 million.

The proposed transaction comes as GE HealthCare reviews its broader portfolio. In July, the company announced a “comprehensive review of strategic options” for its Patient Care Solutions division as part of efforts to refocus the business.

GE HealthCare has faced a weaker stock market performance than the other publicly traded companies created through the breakup of General Electric. Since its January 2023 spin-off, GE HealthCare shares have gained about 12%, while GE Vernova and GE Aerospace have recorded substantially stronger market gains.

Meanwhile, investor Nelson Peltz’s Trian Fund Management has increased its position in GE HealthCare. A July regulatory filing showed that Trian held nearly $200 million worth of the company’s stock.

GE HealthCare declined to comment on the potential transaction. Sofie Biosciences and Trilantic had not immediately responded to requests for comment.

Stay tuned for more such updates on Digital Health News